SEC Comment Letter for NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509) — Jan 6, 2020
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: Jan. 6, 2020 · CIK: 0000810509 · Accession: 0000000000-20-000094
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235762
Letter
January 6, 2020 Jed A. Latkin Chief Executive Officer Navidea Biopharmaceuticals, Inc. 4995 Bradenton Avenue, Suite 240 Dublin, OH 43017-3552 Re:Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 31, 2019 File No. 333-235762 Dear Mr. Latkin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Faith L. Charles, Esq.
Show Raw Text
January 6, 2020
Jed A. Latkin
Chief Executive Officer
Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue, Suite 240
Dublin, OH 43017-3552
Re:Navidea Biopharmaceuticals, Inc.
Registration Statement on Form S-3
Filed December 31, 2019
File No. 333-235762
Dear Mr. Latkin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Faith L. Charles, Esq.